Oruka Therapeutics Inc (ORKA) News

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Oruka Therapeutics Announces $200 Million Private Placement

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”...

Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19

ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected...

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities